ESALY Overview
Upcoming Projects (ESALY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ESALY)
-
A second follow up on Biogen's Lecanemab after presentation of the Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at the Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Tickers: BIIB, ESALY
Executed On: Dec 07, 2022 at 09:00 AM EST -
A follow up on Biogen's Lecanemab after presentation of the Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at the Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Tickers: BIIB, ESALY
Executed On: Dec 05, 2022 at 12:00 PM EST -
An international look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Sep 01, 2022 at 12:45 PM EDT -
A third look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 31, 2022 at 10:00 AM EDT -
A second look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 29, 2022 at 03:00 PM EDT -
A look at Quviviq prescribing patterns since its FDA approval in May for treatment in adults with insomnia and how it compares to Merck's Belsomra and Eisai's Dayvigo.
Tickers: IDRSF, MRK, ESALY
Executed On: Aug 25, 2022 at 05:15 PM EDT
Upcoming & Overdue Catalysts (ESALY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ESALY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
